| Entry |
|
|---|
| Name |
Daunorubicin hydrochloride (JP18/USP);
Cerubidine (TN) |
|---|
| Product |
|
|---|
| Generic |
|
|---|
| Formula |
C27H29NO10. HCl
|
|---|
| Exact mass |
563.1558
|
|---|
| Mol weight |
563.9808
|
|---|
| Structure |
|
|---|
| Simcomp |
|
|---|
| Class |
Antineoplastic
DG01682 Anthracycline antineoplastic
DG01529 Topoisomerase inhibitor
DG01527 Topoisomerase II inhibitor
|
|---|
| Remark |
| Therapeutic category: | 4235 |
| Product (DG00697): | D01264<JP/US> |
| Product (mixture): | D11390<US> |
|
|---|
| Efficacy |
Antineoplastic, Topoisomerase II inhibitor |
|---|
| Disease |
Acute nonlymphocytic leukemia, myelogenous [DS: H00003] Acute lymphocytic leukemia [DS: H00001 H00002] |
|---|
| Target |
|
|---|
| Interaction |
|
|---|
| Structure map |
| map07042 | Antineoplastics - agents from natural products |
|
|---|
| Other map |
|
|---|
| Brite |
Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
L ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
L01 ANTINEOPLASTIC AGENTS
L01D CYTOTOXIC ANTIBIOTICS AND RELATED SUBSTANCES
L01DB Anthracyclines and related substances
L01DB02 Daunorubicin
D01264 Daunorubicin hydrochloride (JP18/USP) <JP/US>
USP drug classification [BR:br08302]
Antineoplastics
Molecular Target Inhibitors
Daunorubicin
D01264 Daunorubicin hydrochloride (JP18/USP)
Therapeutic category of drugs in Japan [BR:br08301]
4 Agents affecting cellular function
42 Antineoplastics
423 Antibiotics
4235 Anthracycline antibiotics
D01264 Daunorubicin hydrochloride (JP18/USP)
Drug groups [BR:br08330]
Antineoplastic
DG01682 Anthracycline antineoplastic
DG00697 Daunorubicin
D01264 Daunorubicin hydrochloride
DG01529 Topoisomerase inhibitor
DG01527 Topoisomerase II inhibitor
DG00697 Daunorubicin
D01264 Daunorubicin hydrochloride
Target-based classification of drugs [BR:br08310]
Enzymes
Isomerases (EC5)
DNA topoisomerase
TOP2
D01264 Daunorubicin hydrochloride (JP18/USP) <JP/US>
Drugs listed in the Japanese Pharmacopoeia [BR:br08311]
Chemicals
D01264 Daunorubicin hydrochloride
Drug groups [BR:br08330]
Antineoplastic
DG01682 Anthracycline antineoplastic
DG00697 Daunorubicin
DG01529 Topoisomerase inhibitor
DG01527 Topoisomerase II inhibitor
DG00697 Daunorubicin
|
|---|
| Other DBs |
|
|---|
| KCF data |
ATOM 39
1 C8x C 2.1027 -6.0215
2 C8x C 2.1027 -7.4219
3 C8y C 3.2931 -8.1221
4 C8y C 4.5535 -7.4219
5 C8y C 4.5535 -6.0215
6 C8x C 3.2931 -5.3213
7 C5x C 5.7438 -8.1221
8 C8y C 6.9342 -7.4219
9 C8y C 6.9342 -6.0215
10 C5x C 5.7438 -5.3213
11 C8y C 8.1945 -8.1221
12 C8y C 9.3850 -7.4219
13 C8y C 9.3850 -6.0215
14 C8y C 8.1945 -5.3213
15 C1y C 10.5753 -8.1221
16 C1x C 11.8357 -7.4219
17 C1z C 11.8357 -6.0215
18 C1x C 10.5753 -5.3213
19 O2a O 3.2931 -9.5225
20 C1a C 2.1027 -10.2227
21 O5x O 5.7438 -9.5225
22 O5x O 5.7438 -3.9209
23 O1a O 8.1945 -3.9209
24 O1a O 8.1945 -9.5225
25 O2a O 10.5753 -9.5225
26 C1y C 11.7657 -10.2227
27 C5a C 13.0261 -5.3213
28 C1a C 14.2164 -6.0215
29 O5a O 13.0261 -3.9209
30 O1a O 13.0261 -6.9317
31 C1x C 11.7657 -11.6232
32 C1y C 13.0261 -12.3234
33 C1y C 14.2164 -11.6232
34 C1y C 14.2164 -10.2227
35 O2x O 13.0261 -9.5225
36 N1a N 13.0433 -13.7237
37 C1a C 15.4321 -9.5274
38 O1a O 15.4255 -12.3147
39 X Cl 6.4402 -11.8302
BOND 42
1 1 2 2
2 2 3 1
3 3 4 2
4 4 5 1
5 5 6 2
6 1 6 1
7 4 7 1
8 7 8 1
9 8 9 1
10 9 10 1
11 5 10 1
12 8 11 2
13 11 12 1
14 12 13 2
15 13 14 1
16 9 14 2
17 12 15 1
18 15 16 1
19 16 17 1
20 17 18 1
21 13 18 1
22 3 19 1
23 19 20 1
24 7 21 2
25 10 22 2
26 14 23 1
27 11 24 1
28 26 25 1 #Down
29 15 25 1 #Down
30 17 27 1 #Up
31 27 28 1
32 27 29 2
33 17 30 1 #Down
34 26 31 1
35 31 32 1
36 32 33 1
37 33 34 1
38 34 35 1
39 26 35 1
40 32 36 1 #Up
41 34 37 1 #Up
42 33 38 1 #Up
|
|---|
